


# Author Index

VOLUME 21, 2001

- Andreu, Antoni, L., 251  
Arévalo, Jorge, 209
- Bhatia, Kailash P., 69  
Biousse, Valérie, 275  
Bonilla, Eduardo, 251  
Borasio, Gian Domenico, 155  
Bradley, Walter G., 177  
Brashear, Allison, 85  
Brown, Robert H., Jr., 131
- Chalela, Julio A., 399  
Chappell, Amy S., 417  
Cohen, Bruce H., 309  
Conneally, P. Michael, 209
- Dagher, Alain, 23  
Davies, Kay E., 189  
Desai, Mehul, 75  
DiMauro, Salvatore, 251  
Dougherty, Frances E., 303  
Dyken, Mark Eric, 377
- Ebbitt, Brenda, 9  
Eisen, Andrew, 141
- Fink, John K., 199  
Flippen, Charles Curtis, II, 371
- Gálvez-Jiménez, Néstor, 3, 15, 75  
Goebel, Joel A., 391  
Gold, Deborah R., 309
- Hanson, Maurice R., 15, 75  
Hauser, Robert A., 91  
Hopkins, Linton C., 359
- Krawiecki, Nicolas, 337
- Leigh, P. Nigel, 167  
Lin-Dyken, Deborah, 377  
Litvan, Irene, 41
- McQuillen, Michael P., 353  
Miller, Robert G., 155  
Musumeci, Olimpia, 251
- Newman, Nancy J., 275
- Parton, Matthew J., 167  
Pascuzzi, Robert M., 1, 125, 231, 349, 425  
Puschban, Z., 33
- Robberecht, Wim, 127, 131  
Robinson, Brian H., 269  
Rusyniak, Daniel E., 407
- Scherfler, C., 33  
Seppi, K., 33  
Sethi, Kapil D., 59  
Shoffner, John M., 233, 237  
Shoubridge, Eric A., 261  
Sladky, John T., 293, 359  
Stefanova, N., 33  
Stover, Natividad P., 49  
Subramanian, Thyagarajan, 103
- Talbot, Kevin, 189  
Tuite, Paul, 9  
Turner, Martin R., 167
- Verma, Ashok, 177
- Watts, Ray L., 49  
Wenning, G.K., 33  
Wojcieszek, Joanne, 209
- Yamada, Thoru, 377
- Zesiewicz, Theresa A., 91  
Zullo, Steven J., 327



# Subject Index

VOLUME 21, 2001

- Acoustic schwannoma, hemifacial spasm (HFS), etiology, 75-82
- Acute akathisia, dopamine blocking therapy, movement disorders linked to, 61-66
- Acute neuromuscular paralysis, Guillain-Barré syndrome, 403-404
- Adult-onset spinal muscular atrophies (SMA type IV), diagnosis, 180-181
- Aerobic exercise, mitochondrial cytopathies, 313-323
- Airway management, Guillain-Barré syndrome, intensive care management, 400-404
- Allotopic gene expression, mammalian cells, gene therapy, mitochondrial disorders, 327-333
- Alternative medicine, medical training in, 366
- Amino acids, metabolic testing, mitochondrial disorders, 303-308
- Amyotrophic lateral sclerosis (ALS)  
clinical characteristics and management, 155-164  
clinical trial overview, 167-173  
dementia in, 183-184  
motor neuron electrophysiology, 141-152  
pathogenesis, 131-136  
progressive spastic paraparesis and, 199-205  
related motor syndromes, 177-185
- Analgesic rebound headache, case studies and management protocols, 371-375
- Animal models, cell transplantation for Parkinson's disease, 103-111
- Anterior horn cells, hereditary spastic paraparesis (HSP), 200-205
- Antiglutamatergic agents, amyotrophic lateral sclerosis (ALS), clinical characteristics and management, 155-164
- Antioxidants, mitochondrial cytopathies, management of, 320-323
- Antipsychotic drugs, movement disorders and, 59-66
- Apolipoprotein E  $\epsilon 4$  allele, cortical basal degeneration (CBD) diagnosis, 53-56
- Apomorphine, Parkinson's disease treatment, 12-13
- Aromatic amino acid decarboxylase (AAAD), catechol-O-methyltransferase (COMT) inhibitors, 18-22
- Arousal sleep disorders, polysomnographic assessment, 383-389
- Assembly gene defects, respiratory chain disorders, nuclear gene mutations, 263-265
- ATPase6, allotopic gene expression, mammalian cells, mitochondrial disorders, 327-333
- Auditory symptoms, dizziness assessment protocols, 392-397
- Autonomic dysfunction, Guillain-Barré syndrome, intensive care management, 402-404
- Autosomal dominant mitochondrial disease, oxidative phosphorylation disease (OXPHOS), 237-242
- Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), research update on, 72-73
- Autosomal recessive mitochondrial disease, oxidative phosphorylation disease (OXPHOS), 237-242
- Autosomal recessive spinal muscular atrophy (SMA), in children, 190-195
- Balance disorders, assessment protocols, 391-397
- Basal ganglia, neuroimaging studies, 23-30
- Benign focal spinal muscular atrophy, diagnosis, 181-182
- Bioethics  
brain death, 353-358  
neurology, overview, 349-350  
outpatient clinic quality, 359-369  
oxidative phosphorylation disease (OXPHOS), pediatric patients, 337-341
- Biologic therapies, progressive supranuclear palsy (PSP) management, 45-46
- Bone fractures, spinal muscular atrophy (SMA) type 1, 194
- Botulinum toxins  
cervical dystonia management, 85-89  
neuromuscular disease, diagnosis and management, 425-438  
neurotoxic syndromes, 407-415
- Brain death, bioethics and, 353-358
- Brain-derived neurotrophic factor, amyotrophic lateral sclerosis (ALS) clinical trials, 167-173
- Bromocriptine, Parkinson's disease treatment, 10-13
- Bruxism, polysomnographic assessment, 387-389
- Calcium channels, amyotrophic lateral sclerosis (ALS) pathogenesis, 135-136
- Cardiomyopathies, nuclear gene mutations, 261-265
- Carnitine  
metabolic testing, mitochondrial disorders, 303-308  
mitochondrial cytopathies, 309-323
- Caspases, Huntington's disease genetics, 209-222
- Catabolic illness, Guillain-Barré syndrome, intensive care management, 401-404
- Catechol-O-methyltransferase (COMT) inhibitors, Parkinson's disease treatment, 15-22
- Cell transplantation, as Parkinson's disease therapy, 103-111
- Cerebellar hypoplasia, spinal muscular atrophy (SMA) with, 193

- Cerebellopontine angle meningioma, hemifacial spasm (HFS), etiology, 75-82
- Cervical dystonia, botulinum toxins for management of, 85-89
- Cervical Dystonia Severity Scale (CDSS), botulinum toxin therapy, 85-89
- Channelopathies, research update on, 69-73
- Cholinesterase inhibitors, neuromuscular disease, diagnosis and management, 429-438
- Chorea, Huntington's disease, 209-222
- Chronic headache, case studies and management protocols, 371-375
- Chronic progressive external ophthalmoplegia, pathogenesis, 282-287
- Ciliary neurotrophic factor, amyotrophic lateral sclerosis (ALS) clinical trials, 167-173
- Clinical Investigator's Brochure (CIB), drug development protocols, 417-423
- Clinical trial protocols  
amyotrophic lateral sclerosis (ALS), 167-173  
drug development, 417-423
- Coenzyme Q<sub>10</sub>, mitochondrial cytopathies, 309-323
- Cognitive deficits  
cortical basal degeneration (CBD), 49-56  
Parkinson's disease, 29-30
- Computed tomography (CT) imaging, Parkinson's disease and limits of, 25-30
- Conduction studies, amyotrophic lateral sclerosis (ALS) electrophysiology, 142-152
- Confusional arousals, polysomnographic assessment, 383-389
- Cortical basal degeneration (CBD)  
diagnosis and management, 49-56  
differential diagnosis, PET imaging, 23-30  
progressive supranuclear palsy (PSP) differential diagnosis, 42-46
- Cortical blindness, mitochondrial disease, 275-287
- Corticomotoneuron, amyotrophic lateral sclerosis (ALS) electrophysiology, 141-152
- Corticosteroids, neuromuscular disease, diagnosis and management, 429-438
- Cost-effectiveness  
dopamine agonists, 12-13  
outpatient clinic quality and, 366-369
- Cranial computed tomography (CCT), multiple system atrophy (MSA) diagnosis, 36-38
- Creatine, mitochondrial cytopathies, management of, 319-323
- Creutzfeldt-Jakob disease (CJD), amyotrophic lateral sclerosis (ALS), dementia and, 184-185
- Cytochrome oxidase deficiency  
nerve/muscle histopathology, mitochondrial disease, 293-300  
respiratory chain disorders, prenatal diagnosis, 271-273
- Dementia  
amyotrophic lateral sclerosis (ALS), 183-185  
hereditary spastic paraparesis (HSP), 200-205
- Demyelinating neuropathy, nerve/muscle histopathology, mitochondrial disease, 293-300
- Diaphragmatic spinal muscular atrophy (SMA), differential diagnosis, 193
- Dietary therapy, mitochondrial cytopathies, 313-323
- Differential diagnosis  
functional neuroimaging techniques, 22-30  
headache case studies and management, 371-375  
hemifacial spasm (HFS), 80-82  
multiple system atrophy (MSA), 33-38  
progressive supranuclear palsy (PSP), 41-46
- Distal spinal muscular atrophy (SMA), pathogenesis, 194
- Dix-Hallpike maneuver, dizziness assessment protocols, 396-397
- Dizziness, assessment protocols, 391-397
- Dopamine agonists  
catechol-O-methyltransferase (COMT) inhibitors with, 15-22  
movement disorders, 9-13
- Dopamine blocking agents, movement disorders caused by, 59-66
- Dopamine receptor markers, PET imaging using, 27-30
- Dopaminergic agents, cortical basal degeneration (CBD) therapy, 55-56
- Dopamine system, positron emission tomography (PET) imaging of, 24-30
- Dose-response curve, drug development clinical trials, 417-423
- Double-blind studies, drug development clinical trials, 422-423
- Drug development, clinical trial protocols, 417-423
- Drug-induced parkinsonism, dopamine blocking agents and, 59-66
- Drug interaction studies, drug development clinical trials, 421-423
- Dynamic visual acuity, dizziness assessment protocols, 395-397
- Dystonia, botulinum toxin therapy, 86-89
- EAAT2 protein, amyotrophic lateral sclerosis (ALS) pathogenesis, 134-136
- Electrodiagnostic testing, nerve/muscle histopathology, mitochondrial disease, 293-300
- Electromyography, amyotrophic lateral sclerosis (ALS) electrophysiology, needle abnormalities, 143-152
- Electrophysiological studies, cortical basal degeneration (CBD) diagnosis, 52-56
- El Escorial criteria, amyotrophic lateral sclerosis (ALS) electrophysiology, 141-152  
related motor syndromes, 177-185
- Encephalomyopathy, mitochondrial cytopathies, 309-323
- Encephalopathies  
neuro-ophthalmologic conditions, 275-287  
neurotoxic syndromes, 407-415  
oxidative phosphorylation disease, mitochondrial DNA mutations, 251-259  
respiratory chain disorders, nuclear gene mutations, 261-265
- End point selection, amyotrophic lateral sclerosis (ALS) clinical trials, 167-173
- Energy metabolism disorders, prenatal diagnosis, 269-273
- Entacapone, catechol-O-methyltransferase (COMT) inhibitors with, 15-22
- Epidemiology, neurotoxic syndrome management, 407-415
- Ergots, dopamine agonists, 11-13

- Ethical issues  
  brain death, 353-358  
  neurology, overview, 349-350  
  outpatient clinic models, 359-369  
  oxidative phosphorylation disease (OXPHOS), pediatric patients, 337-341
- Excitatory postsynaptic potential (EPSP), amyotrophic lateral sclerosis (ALS) electrophysiology, 141-152
- Excitotoxicity, amyotrophic lateral sclerosis (ALS) pathogenesis, 134-136
- Exercise physiology, oxidative phosphorylation disease, mitochondrial DNA mutations, 256-259
- Facial dyskinesias, unusual causes, 75-82
- Facial myokymia, hemifacial spasm (HFS) differential diagnosis, 80-82
- Familial amyotrophic lateral sclerosis (FALS), pathogenesis, 131-136
- Familial (idiopathic) paroxysmal dyskinesias, research update, 69-73
- Family history, Huntington's disease genetics, 209-222
- Fasciculation  
  amyotrophic lateral sclerosis (ALS), clinical characteristics and management, 158-164  
  amyotrophic lateral sclerosis (ALS) electrophysiology, needle abnormalities, 144-152
- FDOPA, as tracer in PET imaging, 26-30
- Fetal cell transplantation, Parkinson's disease management with, 91-98
- Fetal ventral mesencephalic tissue, cell transplantation for Parkinson's disease, 103-111
- Fixation suppression testing, dizziness assessment protocols, 395-397
- Focal amyotrophies, segmental spinal muscular atrophy (SMA) and, 194
- Folate, mitochondrial cytopathies, management of, 321-323
- Folk music, Huntington's disease research, 209-222
- Fukuta step test, dizziness assessment protocols, 397
- Functional scales, amyotrophic lateral sclerosis (ALS) clinical trials, 170-173
- Gait observation, dizziness assessment protocols, 396-397
- Gaze nystagmus, dizziness assessment protocols, 393-397
- Gene therapy, allotopic gene expression, mammalian cells, mitochondrial disorders, 327-333
- Genetic testing, oxidative phosphorylation disease (OXPHOS), pediatric patients, 337-341
- Glial cytoplasmic inclusions (GCI), multiple system atrophy (MSA), 34-38
- Glutamate transporters, amyotrophic lateral sclerosis (ALS) pathogenesis, 134-136
- Guillain-Barré syndrome, intensive care management, 399-404
- Guthrie, Woody, Huntington's disease research and, 209-222
- Half-lives, dopamine agonists, 11-13
- Headache, case studies and management protocols, 371-375
- Head thrust test, dizziness assessment protocols, 395-397
- Health care reform, brain death issues, 353-358
- Heavy metals exposure, neurotoxic syndromes, 407-415
- Hemicrania continua, case studies and management protocols, 371-375
- Hemifacial spasm (HFS), unusual etiology, 75-82
- Hereditary spastic paraparesis (HSP)  
  diagnosis, 179  
  progressive spastic paraparesis and, 199-205
- Heteroplasmy  
  gene therapy, allotopic gene expression, 327-333  
  oxidative phosphorylation disease, mitochondrial DNA mutations, 253-259
- Hirayama's disease  
  diagnosis, 181-182  
  segmental spinal muscular atrophy (SMA) and, 194
- History of neurology, Woody Guthrie case study, 209-222
- Homonymous hemianopia, mitochondrial mutations, 275-287
- Human retinal pigment epithelial cell transplantation, Parkinson's disease management with, 91-98, 103-111
- Huntingtin protein, Huntington's disease, 209-222
- Huntington's disease, Woody Guthrie case study, 209-222
- Hyperventilation, dizziness assessment protocols, 397
- Idebenone, mitochondrial cytopathies, management of, 318-323
- Idiopathic stabbing headache, case studies and management protocols, 371-375
- Imaging techniques  
  cortical basal degeneration (CBD) diagnosis, 49-56  
  multiple system atrophy (MSA), 33-38  
  PET imaging, Parkinson's disease differential diagnosis, 23-30  
  progressive supranuclear palsy (PSP) diagnosis, 42-46
- Immune therapy  
  Guillain-Barré syndrome, 403-404  
  neuromuscular disease, diagnosis and management, 425-438
- Immunoglobulins, neuromuscular disease, diagnosis and management, 431-438
- Infantile convulsions and choreoathetosis (ICCA) syndrome, research update on, 70-73
- Informed consent  
  brain death and, 353-358  
  oxidative phosphorylation disease (OXPHOS), pediatric patients, 337-341
- Insulin-like growth factor-1, amyotrophic lateral sclerosis (ALS) clinical trials, 167-173
- Insurance issues, oxidative phosphorylation disease (OXPHOS), pediatric patients, 337-341
- Intensive care management, Guillain-Barré syndrome, 399-404
- Intermediate alleles, Huntington's disease genetics, 209-222
- Intranigral transplantation technique, cell transplantation for Parkinson's disease, 103-111
- KCNA1 gene, paroxysmal kinesigenic choreoathetosis/dyskinesias (PKC/PKD), 69-73
- Kennedy's disease (X-linked bulbospinal muscular atrophy), diagnosis, 181
- Lactate, metabolic testing, mitochondrial disorders, 303-308
- Lambert-Eaton syndrome, diagnosis and management, 425-438

- Leber's hereditary optic neuropathy (LHON)  
oxidative phosphorylation disease (OXPHOS), 242  
pathogenesis, 275-287
- Leigh syndrome  
gene therapy, allotopic gene expression, 327-333  
nuclear gene mutations, 261-265
- Levodopa/carbidopa  
catechol-*O*-methyltransferase (COMT) inhibitors and, 15-22  
Parkinson's disease treatment, 9-13
- Limb coordination testing, dizziness assessment protocols, 396-397
- Lipid peroxidation, progressive supranuclear palsy (PSP) management, 45-46
- Lower motor neurons, amyotrophic lateral sclerosis (ALS)  
electrophysiology, 141-152  
related motor syndromes, 177-185
- Magnetic resonance imaging (MRI), Parkinson's disease and limits of, 23-30
- Mastoid oscillation, dizziness assessment protocols, 397
- Maternal inheritance, oxidative phosphorylation disease, mitochondrial DNA mutations, 251-259
- Medical care quality, outpatient clinic models, 359-369
- Medical education, outpatient clinic visits, 359-369
- Metabolic testing  
mitochondrial disorders, 303-308  
Parkinsonian and other movement disorders, 26-30
- Migraine headache, case studies and management protocols, 374-375
- Miller-Fisher syndrome, botulism with, 407-415
- Mitochondrial cytopathies, management of, 309-323
- Mitochondrial disorders  
cytopathies, management of, 309-323  
energy metabolism disorders, prenatal diagnosis, 269-273  
metabolic testing, 303-308  
MtDNA mutations, gene therapy, 327-333  
neuro-ophthalmology, 275-287  
oxidative phosphorylation disease  
mitochondrial DNA mutations, 251-259  
research status, 237-242  
peripheral nerve and muscle histopathology, 293-300  
research status, 233-234  
respiratory chain disorders, nuclear gene defects, 261-265
- Mitochondrial DNA  
gene therapy, mitochondrial disorders, 327-333  
oxidative phosphorylation disease (OXPHOS), 237-242
- Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), neuro-ophthalmological symptoms, 275-287
- Mitochondrial iron overload, respiratory chain activity, 265
- Mitochondrial targeting leader sequence, gene therapy, allotopic gene expression, 327-333
- Mitotic segregation, oxidative phosphorylation disease, mitochondrial DNA mutations, 253-259
- Monomelic amyotrophy, diagnosis, 181-182
- Motor neuron diseases  
amyotrophic lateral sclerosis  
clinical characteristics and management, 155-164  
clinical trial overview, 167-173  
electrophysiology, 141-152  
pathogenesis, 131-136  
atypical disease, related motor syndromes, 177-185  
Huntington's disease, 209-222  
progressive spastic paraparesis and related syndromes, 199-205  
research overview, 127  
spinal muscular atrophy (SMA), 189-195
- Motor unit estimates (MUNE)s, amyotrophic lateral sclerosis (ALS) electrophysiology, needle abnormalities, 146-152
- Movement disorders  
catechol-*O*-methyltransferase (COMT) inhibitors, pharmacokinetics, 15-22  
cervical dystonia, botulinum toxins for, 85-89  
corticobasal degeneration (CBD), 49-56  
differential diagnosis, PET imaging, 23-30  
dopamine agonists, 9-13  
dopamine blocking agents as cause of, 59-66  
familial (idiopathic) paroxysmal dyskinesias, 69-73  
hemifacial spasm (HFS), etiology, 75-82  
multiple system atrophy (MSA), 33-38  
Parkinson's disease  
cell transplantation therapy, 103-111  
neurosurgery for, 91-98  
progressive supranuclear palsy (PSP) diagnosis and management, 41-46  
research overview, 3-5
- MtDNA depletion syndrome, prenatal diagnosis, 271-273
- Multifocal motor neuropathy (MMN)  
amyotrophic lateral sclerosis (ALS) electrophysiology, 142-152  
diagnosis, 183
- Multiple system atrophy (MSA), differential diagnosis  
PET imaging, 23-30  
therapy and, 33-38
- Muscle disorders, mitochondrial disease, 293-300
- Myasthenia gravis, diagnosis and management, 425-438
- Myoclonus toxicology, neurotoxic syndromes, 407-415
- NADH-ubiquinone oxidoreductase, respiratory chain disorders, prenatal diagnosis, 271-273
- National Institute of Neurological Diseases and Stroke (NINDS), progressive supranuclear palsy (PSP) diagnostic criteria, 42-46
- Nerve disorders, mitochondrial disease, 293-300
- Nervous system disease, dizziness assessment protocols, 392-397
- Neural transplantation, cell transplantation for Parkinson's disease, 103-111
- Neurofilament heavy subunit (NF-H), familial amyotrophic lateral sclerosis (FALS) pathogenesis, 133-136
- Neuroimaging studies, oxidative phosphorylation disease, mitochondrial DNA mutations, 256-259
- Neuroleptic malignant syndrome, dopamine blocking therapy and, 66
- Neuroleptic therapy, movement disorders linked to, 62-66
- Neurology, ethical issues overview, 349-350  
brain death, 353-358  
outpatient clinics, 359-369
- Neuromuscular junction disorders, diagnosis and management, 425-438

- Neuronal damage, cortical basal degeneration (CBD)  
diagnosis, 53-56
- Neuro-ophthalmologic disorders, mitochondrial disease,  
275-287
- Neurosurgery, Parkinson's disease management with, 91-98
- Neurotoxicology, neurotoxic syndrome management,  
407-415
- Neurotoxic syndromes, case studies and management  
protocols, 407-415
- Neurotoxins, atypical motor neuron disease, 180
- Neurotransmitters, PET imaging and, 28-30
- Nocturnal seizures, polysomnographic assessment, 377-389
- Node of Ranvier, nerve/muscle histopathology, mitochondrial  
disease, 293-300
- Noninvasive ventilation, amyotrophic lateral sclerosis (ALS),  
clinical characteristics and management, 155-164
- Nonsteroidal immunosuppressive therapy, neuromuscular  
disease, diagnosis and management, 431-438
- Nuclear gene mutations  
energy metabolism disorders, prenatal diagnosis, 270-273  
oxidative phosphorylation disease (OXPHOS), 237-242  
respiratory chain disorders, 261-265
- Nuclear-mitochondrial communication disorders, respiratory  
chain activity, 264-265
- Nystagmus, dizziness assessment protocols, 393-397
- Olivopontocerebellar (OPCA) pathways, multiple system  
atrophy (MSA), 36-38
- Ophthalmoplegia, pathogenesis, 275-287
- Optic atrophy, mitochondrial disease, 278-287
- Optic neuropathy, mitochondrial disease, 275-287
- Organic acids, metabolic testing, mitochondrial disorders,  
303-308
- Orobuccolingual dyskinesia (OBD), dopamine blocking  
therapy and, 62-66
- Oxidative phosphorylation disease (OXPHOS)  
gene therapy, allotopic gene expression, 327-333  
metabolic testing, 303-308  
mitochondrial DNA mutations, 251-259  
pediatric patients, ethical issues, 337-341  
research status, 237-242
- Pain syndromes, Guillain-Barré syndrome, intensive care  
management, 402-404
- Palliative care, amyotrophic lateral sclerosis (ALS), clinical  
characteristics and management, 155-164
- Pallidal stimulation, Parkinson's disease management with,  
91-98
- Pallidotomy, Parkinson's disease management with, 91-98
- Paracrystalline inclusions, nerve/muscle histopathology,  
mitochondrial disease, 293-300
- Paraplegin, progressive spastic paraparesis pathogenesis,  
199-205
- Parasomnias, polysomnographic assessment, 377-389
- Parkinsonian disorders  
neurotoxic syndromes, 407-415  
progressive supranuclear palsy (PSP), 41-46
- Parkinsonism, amyotrophic lateral sclerosis (ALS), dementia  
and, 184
- Parkinson's disease  
catechol-O-methyltransferase inhibitors, 15-22  
cell transplantation therapy, 103-111  
dopamine agonists, 9-13  
functional imaging in, 23-30  
neurosurgical management of, 91-98
- Parotid gland tumor, hemifacial spasm (HFS), etiology, 75-82
- Paroxysmal exercise-induced dyskinesia (PED), research  
update on, 71-73
- Paroxysmal kinesigenic choreoathetosis/dyskinesias  
(PKC/PKD), research update, 69-73
- Patient positioning, Guillain-Barré syndrome, intensive care  
management, 401-404
- Pediatric patients, oxidative phosphorylation disease  
(OXPHOS), ethical issues, 337-341
- Pergolide, Parkinson's disease treatment, 11-13
- Peripheral nervous system  
dizziness assessment protocols, 392-397  
neurotoxic syndromes, 407-415
- Peristimulus time histograms (PSTHs), amyotrophic lateral  
sclerosis (ALS) electrophysiology, 141-152
- Pharmacokinetics  
catechol-O-methyltransferase (COMT) inhibitors, 15-22  
drug development protocols, 417-423  
neurotoxic syndromes, 407-415
- Physical examination protocols, dizziness assessment,  
391-397
- Pigmentary retinopathy, pathogenesis, 284-287
- Placebo controls, drug development clinical trials, 422-423
- Plasma exchange, neuromuscular disease, diagnosis and  
management, 425-438
- Pneumatic otoscopy, dizziness assessment protocols, 397
- Polysomnographic assessment, sleep disorders, 377-389
- Porcine cell transplantation, Parkinson's disease management  
with, 91-98, 103-111
- Positional testing, dizziness assessment protocols, 396-397
- Positron emission tomography (PET), Parkinson's disease  
imaging, 23-30
- Postheadshake nystagmus, dizziness assessment protocols,  
395-397
- Postpoliomyelitis muscular atrophy (PMMA), diagnosis, 182
- Pramipexole, Parkinson's disease treatment, 11-13
- Prenatal diagnostic procedures, energy metabolism disorders,  
269-273
- Preventive therapy, amyotrophic lateral sclerosis (ALS),  
clinical characteristics and management, 158-164
- Primary lateral sclerosis (PLS)  
diagnosis, 178-179  
progressive spastic paraparesis and, 199-205
- Prognosis protocols, Guillain-Barré syndrome, intensive care  
management, 404
- Progressive muscular atrophy (PMA), diagnosis, 180
- Progressive spastic paraparesis, related motor syndromes,  
199-205
- Progressive supranuclear palsy (PSP)  
diagnosis and management, 41-46  
differential diagnosis, PET imaging, 23-30
- Proof of concept trial, drug development clinical trials,  
421-423
- Proxysmal hypnogenic dyskinesia (PHD), research update on,  
71-73
- Pseudobulbar effect, amyotrophic lateral sclerosis (ALS),  
clinical characteristics and management, 155-164

- Pseudo-myasthenic ptosis, neuromuscular disease, diagnosis and management, 428-438
- Psychiatric illness  
dizziness assessment protocols, 392-397  
dopamine blocking therapy, movement disorders linked to, 59-66  
sleep disorders, polysomnographic assessment, 378-389
- Psychic problems, amyotrophic lateral sclerosis (ALS), clinical characteristics and management, 162-164
- Psychogenic movement, hemifacial spasm (HFS), etiology, 75-82
- Public health services, outpatient clinic quality, 359-369
- Pyramidal neurons, hereditary spastic paraparesis (HSP), 200-205
- Pyruvate carboxylase deficiency, prenatal diagnosis, 270-273
- Pyruvate dehydrogenase deficiency, prenatal diagnosis, 270-273
- Pyruvates, metabolic testing, mitochondrial disorders, 303-308
- Quality issues in medical care, outpatient clinic quality, 359-369
- Quality of life scales, amyotrophic lateral sclerosis (ALS) clinical trials, 170-173
- Questionnaires, dizziness assessment using, 392-397
- Quinn diagnostic criteria, multiple system atrophy (MSA), 34-38
- Ragged-red fiber, nerve/muscle histopathology, mitochondrial disease, 293-300
- Rapid eye movement (REM) sleep disorders, polysomnographic assessment, 386-389
- Respiratory chain disorders  
nuclear gene mutations, 261-265  
oxidative phosphorylation disease, mitochondrial DNA mutations, 251-259  
prenatal diagnosis, 271-273
- Respiratory dysfunction, Guillain-Barré syndrome, intensive care management, 400-404
- Retrochiasmal loss, pathogenesis, 284-287
- Rhythmic movement disorder, polysomnographic assessment, 384-389
- Riboflavin, mitochondrial cytopathies, management of, 320-323
- Riluzole  
amyotrophic lateral sclerosis (ALS), clinical characteristics and management, 158-164  
amyotrophic lateral sclerosis (ALS) clinical trials, 167-173
- Risk assessment  
dopamine blocking therapy, movement disorders linked to, 59-66  
oxidative phosphorylation disease (OXPHOS), pediatric patients, 337-341
- Rolandic epilepsy, research update on, 72-73
- Romberg testing, dizziness assessment protocols, 396-397
- Ropinirole, Parkinson's disease treatment, 11-13
- Rural health care, outpatient clinic quality, 359-369
- Saccades, dizziness assessment protocols, 393-397
- Safety issues, drug development clinical trials, 422-423
- Scapulohumeral spinal muscular atrophy (SMA), pathogenesis, 194
- Schizophrenia, movement disorders and therapy for, 59-66
- Segmental spinal muscular atrophy (SMA), pathogenesis, 194
- Sensory nerve action potentials (SNAPs), amyotrophic lateral sclerosis (ALS) electrophysiology, 142-152
- Side effects  
analgesic rebound headache, 375  
dopamine agonists, 12-13  
dopamine blocking therapy, movement disorders linked to, 59-66
- Sinemet, Parkinson's disease treatment, 9-13
- Single photon emission computed tomography (SPECT)  
multiple system atrophy (MSA), 36-38  
Parkinson's disease imaging, 23-30
- Sleep-related disorders, polysomnographic assessment, 377-389
- Sleep-wake transition disorders, polysomnographic assessment, 384-389
- Sleepwalking, polysomnographic assessment, 384-389
- Smooth pursuit testing, dizziness assessment protocols, 393-397
- SOD1* gene, amyotrophic lateral sclerosis pathogenesis, 131-136
- Sodium dichloroacetate, mitochondrial cytopathies, management of, 314-323
- Solvent exposure, neurotoxic syndromes, 407-415
- Somatic mutations  
gene therapy, allotopic gene expression, 327-333  
oxidative phosphorylation disease, mitochondrial DNA mutations, 255-259
- Spastin, progressive spastic paraparesis pathogenesis, 199-205
- Spinal bulbar muscular atrophy (XSBMA), familial amyotrophic lateral sclerosis (FALS) pathogenesis, 133-136
- Spinal cord disease, progressive spastic paraparesis and, 199-205
- Spinal muscular atrophy (SMA)  
childhood variants, differential diagnosis, 193-195  
pathogenesis, 189-195
- Spontaneous nystagmus, dizziness assessment protocols, 393-397
- Sporadic amyotrophic lateral sclerosis (SALS), pathogenesis, 131-136
- SR57746A, amyotrophic lateral sclerosis (ALS) clinical trials, 167-173
- Striatonigral degeneration (SND)  
differential diagnosis, PET imaging, 25-30  
multiple system atrophy (MSA), 36-38
- Structural gene defects, respiratory chain disorders, nuclear gene mutations, 262-265
- Structural imaging, Parkinson's disease and limits of, 23-30
- Strümpell-Lorrain syndrome. *See* Progressive spastic paraparesis
- Subthalamic nucleus stimulation, Parkinson's disease management with, 91-98
- Succinate-CoQ oxidoreductase, respiratory chain disorders, prenatal diagnosis, 271-273
- Succinate dehydrogenase, nerve/muscle histopathology, mitochondrial disease, 293-300
- Superoxide dismutase, amyotrophic lateral sclerosis pathogenesis, 131-136

- Surrogate markers  
  amyotrophic lateral sclerosis (ALS) clinical trials, 167-173  
  drug development clinical trials, 421-423
- Survival motor neurons, spinal muscular atrophy (SMA), 189-195
- Symptom control, amyotrophic lateral sclerosis (ALS), clinical characteristics and management, 158-164
- Tardive dyskinesia, dopamine blocking agents and, 59-66
- Tardive dystonia, dopamine blocking therapy and, 62-66
- Tau protein  
  cortical basal degeneration (CBD) diagnosis, 53-56  
  progressive supranuclear palsy (PSP) management, 45-46
- Teaching protocols, outpatient clinics, 359-369
- Thalamic stimulation, Parkinson's disease management with, 91-98
- Thalamotomy, Parkinson's disease management with, 91-98
- Thiamine, mitochondrial cytopathies, management of, 321-323
- Threshold effect, oxidative phosphorylation disease, mitochondrial DNA mutations, 253-259
- Thymectomy, neuromuscular disease, diagnosis and management, 429-438
- Tick paralysis, neuromuscular disease, diagnosis and management, 425-438
- Tolcapone, catechol-*O*-methyltransferase (COMT) inhibitors with, 15-22
- Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), botulinum toxin therapy, 85-89
- Tracheostomy, Guillain-Barré syndrome, complications, 404
- Tragal compression testing, dizziness assessment protocols, 397
- Transformed migraine headache, case studies and management protocols, 375
- Transplantation surgery, cell transplantation for Parkinson's disease, 103-111
- Trigeminal autonomic cephalgias, case studies and management protocols, 371-375
- Tullio phenomenon, dizziness assessment protocols, 397
- Unified Parkinson's Disease Rating Scale (UPDRS), catechol-*O*-methyltransferase (COMT) inhibitors, 19-22
- Upper motor neurons, amyotrophic lateral sclerosis (ALS) electrophysiology, 141-152  
  related motor syndromes, 177-185
- Uridine, mitochondrial cytopathies, management of, 322
- Valsalva maneuver, dizziness assessment protocols, 397
- Vascular loop compression, hemifacial spasm (HFS), etiology, 75-82
- Vegetative state, ethical issues concerning, 353-358
- Vertigo, assessment protocols, 391-397
- Vestibular ocular reflex, assessment protocols, 391-397
- Visual analog scales, botulinum toxin therapy assessment, 88-89
- Vitamins and supplements, mitochondrial cytopathies, management of, 316-323
- "Wearing off" effect, Parkinson's disease treatment, 15-22
- Werdnig-Hoffmann disease, spinal muscular atrophy (SMA) differential diagnosis, 193-195
- X-linked arthrogryposis multiplex congenita-SMA, differential diagnosis, 193
- X-linked bulbospinal muscular atrophy, diagnosis, 181